This study shows for the first time that TTD, which exhibited the highest inhibition of NR4A1-dependent activity among FCN analogs, directly binds to the LBD of NR4A1 and antagonizes NR4A1-mediated transactivation in cancer cells. The gene discussed is NR4A1; the disease is cancer.